Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Otorhinolaryngol. Feb 28, 2016; 6(1): 13-18
Published online Feb 28, 2016. doi: 10.5319/wjo.v6.i1.13
Management of intratemporal facial nerve schwannomas: The evolution of treatment paradigms from 2000-2015
Luv Makadia, Sarah E Mowry
Luv Makadia, Sarah E Mowry, Department of Otolaryngology, Georgia Regents University, Augusta, GA 30907, Untied States
Author contributions: Both authors contributed equally to this work.
Conflict-of-interest statement: Neither author has conflicts of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Sarah E Mowry, MD, Department of Otolaryngology, Georgia Regents University, 1120 15th Street, Augusta, GA 30907, Untied States. smowry@gru.edu
Telephone: +1-706-7216100 Fax: +1-706-7210112
Received: August 28, 2015
Peer-review started: September 1, 2015
First decision: November 27, 2015
Revised: December 18, 2015
Accepted: January 21, 2016
Article in press: January 22, 2016
Published online: February 28, 2016
Processing time: 182 Days and 12.6 Hours
Abstract

Intratemporal facial nerve schwannoma (FNS) are rare benign tumors of the skull base. Many of these tumors will be detected during evaluation for symptoms suggestive of vestibular schwannoma. However, there are several signs and symptoms which can suggest the facial nerve as the origin of the tumor. Intratemporal FNS can be multiple, like “beads on a string”, or solitary lesions of the internal auditory canal. This variable tumor morphology necessitates multiple treatment options to allow patients the best chance of preservation of facial nerve function. Historically FNS were managed with resection of the nerve with cable grafting. However this leaves the patient with permanent facial weakness and asymmetry. Currently most patients find this outcome unacceptable, especially when they present with good to normal facial nerve function. Facial paralysis has a significantly negative impact on quality life, so treatment regimens that spare facial nerve function have been used in patients who present with moderate to good facial nerve function. Nerve sparing options include tumor debulking, decompression of the bony facial canal, radiosurgery, and observation. The choice of management depends on the degree of facial nerve dysfunction at presentation, hearing status in the affected ear, medical comorbidities and patient preference. Each treatment option will be discussed in detail and suggestions for patient management will be presented.

Keywords: Facial nerve schwannoma; Middle cranial fossa; Intratemporal; Translabyrinthine; Stereotactic radiosurgery; Cable graft; Tumor stripping; Facial nerve decompression

Core tip: The management of intratemporal facial nerve schwannoma (FNS) has changed over the past 15 years. Current management strategies involve tumor stripping, bony decompression, radiosurgery, and observation. Each of these treatment options are designed to minimize the risk of injury to a functional facial nerve. Complete surgical excision and cable grafting are reserved for tumors which have already resulted in severe facial weakness. Each management strategy will be discussed in detail with a management algorithm will be presented. Intratemporal FNS are unusual benign tumors affecting the facial nerve as it passes through the bony canal of the temporal bone. Previous management paradigms involved complete resection of the tumor and nerve with simultaneous cable grafting; however, patients were left with long term facial paresis. Newer treatment strategies resulting in less facial nerve morbidity have become more popular in the last 15 years including: Surgical debulking, stereotactic radiosurgery, bony decompression and observation. Each of these strategies will be discussed with emphasis on facial nerve outcomes and tumor control rates.